Oligohydramnios as Prognostic Factor for Maternal Risk in Term Pregnancy and Fetal Outcome
Abstract
Objective: To investigate oligohydramnios as prognostic factor for maternal risk in term pregnancy and its fetal outcome.
Methodology: This descriptive cross sectional study was conducted in the department of Obstetrics and Gynecology Combined Military Hospital, Muzaffarabad in a period of one year from October 2021 to October 2022.
All of the patients with an oligohydramnios diagnosis were included in this cross-sectional research. Patients who met our selection criteria were enrolled utilizing a non-probability consecutive sampling procedure. Every person who was selected was informed about the study's methodology, and the researcher acquired their signed informed consent. The following were noted: demographic data, patient clinical traits, obstetrical problems, and delivery method. Maternal and newborn outcomes during inpatient care were examined and recorded.
Results: The main age of study sample was 27.73 ± 4.75 years and mean gestational age was 38.42 ± 2.20 weeks. Majority 73.4% of the patients had normal weight and most of the women (82.8%) had no comorbid disease. Only (9.4%) of the women in the study had a history of oligohydramnios in previous pregnancy. Most of the women (92.2%) in the study sample delivered with caesarian section. The mean birth weight of the babies was 2.77 ± 0.51 kg. 10 (15.6%) babies required admission to NICU. The birth weight and APGAR score at 1 and 5 minutes did not show any significant (p-value > 0.05) association with body mass index of the mother.
Conclusions: Oligohydramnios is a frequent pregnancy issue that has been linked to an elevated risk of unfavorable postnatal outcomes since it is thought to be a sign of foetal impairment. With proper foetal surveillance, frequent antenatal care visits, and other measures may help to reduce perinatal morbidity and mortality.
Copyright (c) 2023 Journal of The Society of Obstetricians and Gynaecologists of Pakistan

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.